Use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow in antilymphocyte serum-treated mice: the unique effect of sirolimus.
Tolerance produced with ALS treatment, DSBM, and sirolimus involves multiple mechanisms of a specific and nonspecific nature. In eventual clinical application for tolerance induction, sirolimus (rapamycin) has great potential for augmenting the tolerogenicity of the ALS/BM regimen.
Hale
D
D
Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02158, USA.
Gottschalk
R
R
Maki
T
T
Monaco
A P
AP
D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D011090:Polyenes / Q000627:therapeutic use*; D020123:Sirolimus; D016038:Skin Transplantation / Q000276:immunology*; D014158:Transcription, Genetic; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D016207:Cytokines; D007166:Immunosuppressive Agents; D011090:Polyenes; D020123:Sirolimus